Old Articles: <Older 8331-8340 Newer> |
|
Chemistry World June 12, 2012 Nina Notman |
More testing needed for ridaforolimus US pharma company Merck & Co has confirmed that marketing approval for its anti-cancer drug ridaforolimus has been held up by the US Food and Drug Administration. |
CRM June 2012 Leonard Klie |
Modern Medicine: A Marketing Headache When it comes to customer self-service, the medical industry is far ahead of many other verticals in its use of technology, but customer use of those options is still far from prevalent. |
Searcher June 2012 Stephanie C. Ardito |
The Medical Digital: How Safe Are the Prescription Drugs we Take? Monitoring Adverse Events and Recalls For general information about prescription and clinical trial drugs, the following websites have been around for a while and have excellent reputations. |
Chemistry World May 30, 2012 |
Takeda buys into Brazil for 540m reals Brazilian company Multilab made sales of BRL140 million in 2011, primarily from generics and over-the-counter branded products, including its leading cold and flu brand Multigrip. |
Pharmaceutical Executive May 1, 2012 William Looney |
Information Overload Data has become as important as the drug in driving success in healthcare. |
Chemistry World May 23, 2012 Andy Extance |
Drug watchdogs mark out global territory The US Food and Drug Administration has published plans to ensure that American citizens continue to enjoy access to safe drugs, even as the regulatory pressures of globalization grow. |
Pharmaceutical Executive May 1, 2012 |
The Personal Touch in Digital Promotion The shift from sales rep meetings to digital selling methods must include innovation and a physician-centered mindset in order to be successful. |
Pharmaceutical Executive May 1, 2012 |
Value-Based Pricing: Too High a Price for UK Pharma? Changes to the system in the UK could finally put some real metrics behind the elusive concept of value but with payers clearly in the driver's seat, who needs clarity? |
Pharmaceutical Executive May 1, 2012 |
Pharm Exec 50: Growth from the Bottom Up More consolidation didn't boost pharmaceutical sales at the top, but a handful of nimble newcomers posted impressive growth on the other end of the curve. |
Pharmaceutical Executive May 1, 2012 William Looney |
Seeding Beyond the Base The pharmaceutical industry's reputation as a growth industry no one wants to pay for is more secure than ever. |
<Older 8331-8340 Newer> Return to current articles. |